Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

The Treatment Strategy: Balancing Calcium and Kidney Health

At a Glance

ADH treatment requires maintaining low-normal blood calcium to prevent symptoms while protecting your kidneys from damage. Standard care involves calcium, vitamin D, magnesium, and diuretics. New emerging calcilytic drugs are also being studied to directly fix the overactive calcium sensor.

Managing Autosomal Dominant Hypocalcemia (ADH) requires a unique treatment strategy that often contradicts “standard” medical goals. Unlike many other conditions where the aim is to bring lab results into the normal range, the goal in ADH is to maintain a delicate balance that protects both your comfort and your long-term kidney health.

The Calcium Balancing Act

In most cases of low calcium, doctors try to bring blood levels back to a “normal” laboratory range. However, for patients with ADH, doing so can be dangerous [1].

Because your body’s “calcium sensor” is overactive, it constantly tries to flush calcium out of your system through your urine [2][3]. If you take enough supplements to reach a “normal” blood calcium level, your kidneys will work even harder to dump that “excess” calcium, leading to high urine calcium (hypercalciuria) [1][4]. This significantly increases your risk for kidney stones and permanent kidney damage [5][6].

The Goal: Most experts recommend maintaining low-normal serum calcium levels—just high enough to prevent symptoms like tingling or muscle cramps, but not necessarily high enough to meet standard laboratory ranges [4][1].

Conventional Therapy

The “standard” toolkit for ADH includes:

  • Active Vitamin D (Calcitriol): This helps your intestines absorb more calcium from your food [3][4].
  • Calcium Supplements: Used to provide a steady supply of calcium for the body to use [7].
  • Thiazide Diuretics: These are often added because they tell the kidneys to reabsorb calcium back into the blood instead of flushing it out. Important Note: A low-sodium (low-salt) diet is essential to help thiazides work effectively. Additionally, thiazides can cause your body to lose potassium and further deplete magnesium, requiring close lab monitoring [8][9].
  • Magnesium Replenishment: Because the overactive calcium sensor also prevents the kidneys from reabsorbing magnesium, ADH directly causes hypomagnesemia (low blood magnesium). This is a direct manifestation of the disease itself, not just a dietary issue. Uncorrected low magnesium makes your low calcium symptoms worse and harder to treat, so you will likely need prescription-strength supplements [10].

Emerging and Experimental Treatments

Because conventional therapy can be hard on the kidneys, researchers are developing more “targeted” ways to treat the root cause of ADH.

1. Hormone Replacement (rhPTH)

In some forms of hypoparathyroidism, recombinant human parathyroid hormone (like rhPTH 1-84) helps lower urine calcium. However, for ADH specifically, it is often less effective. Because the “broken sensor” in the kidney ignores the PTH signal, rhPTH may fail to resolve the high urine calcium, and in some cases, can even worsen it [4]. It is sometimes used as an alternative therapy, but it is not a perfect fix.

2. Calcilytics: The Future of ADH Care

The most exciting advancement in ADH treatment is a new class of drugs called calcilytics (such as encaleret) [11][12]. These are “negative allosteric modulators”—essentially, they act like a wedge that prevents the overactive calcium sensor from firing [13][14].

  • By “turning down” the sensor, these drugs allow your parathyroid glands to start making their own PTH again [15][14].
  • They also tell the kidneys to stop flushing calcium [5][16].
  • These drugs are currently in clinical trials and represent a shift from managing symptoms to treating the actual genetic mechanism of the disease [11].

Monitoring Your Progress

Because the risk of kidney damage is high, monitoring for ADH is frequent and lifelong. This typically includes regular 24-hour urine collections to measure exactly how much calcium your kidneys are processing and periodic renal ultrasounds to check for early signs of calcium deposits [5][1].

-1 | Symptoms and Complications | Long-Term Monitoring

Common questions in this guide

Why shouldn't my calcium levels be brought up to the normal range?
In ADH, aiming for a completely normal blood calcium level can be dangerous. Because your body constantly flushes calcium into your urine, taking high doses of supplements forces your kidneys to work harder, significantly increasing your risk for kidney stones and permanent organ damage.
How is Autosomal Dominant Hypocalcemia typically treated?
Conventional treatment usually includes active Vitamin D, calcium supplements, and prescription magnesium. Thiazide diuretics may also be prescribed alongside a strict low-salt diet to help the kidneys reabsorb calcium into the blood instead of flushing it out.
What are calcilytics and how do they work for ADH?
Calcilytics are an emerging class of medications that act directly on the body's overactive calcium sensor. By turning down this sensor, they allow your parathyroid glands to produce hormones naturally and tell your kidneys to stop flushing excess calcium into your urine.
What kind of medical monitoring will I need long-term?
Because of the high risk of kidney damage, you will need lifelong monitoring. This typically involves regular 24-hour urine collections to measure your exact calcium excretion and periodic kidney ultrasounds to check for early signs of calcium deposits or stones.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific target range for my serum calcium, and how does this compare to the 'normal' lab range?
  2. 2.Since I have ADH, should we prioritize monitoring my 24-hour urine calcium over my serum calcium?
  3. 3.Would a thiazide diuretic help reduce my urine calcium, and if so, how will we monitor my potassium and magnesium?
  4. 4.Am I a candidate for emerging clinical trials for calcilytics?
  5. 5.How often should I have my kidney function and renal ultrasounds checked while on this treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.

    Roszko KL, Stapleton Smith LM, Sridhar AV, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(10)):1926-1935 doi:10.1002/jbmr.4659.

    PMID: 35879818
  2. 2

    Autosomal dominant hypocalcemia type 1: Status quo of tailored management and future perspectives.

    Harada D, Namba N

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2026; doi:10.1093/jbmr/zjag034.

    PMID: 41732805
  3. 3

    Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.

    De Coster T, David K, Breckpot J, Decallonne B

    Journal of endocrinological investigation 2025; (48(4)):831-844 doi:10.1007/s40618-024-02496-y.

    PMID: 39607645
  4. 4

    Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.

    Hawkes CP, Shulman DI, Levine MA

    European journal of endocrinology 2020; (183(6)):K13-K21.

    PMID: 33112267
  5. 5

    Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH).

    Dong B, Endo I, Ohnishi Y, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2015; (30(11)):1980-93 doi:10.1002/jbmr.2551.

    PMID: 25967373
  6. 6

    Autosomal Dominant Hypocalcemia (Hypoparathyroidism) Types 1 and 2.

    Roszko KL, Bi RD, Mannstadt M

    Frontiers in physiology 2016; (7()):458 doi:10.3389/fphys.2016.00458.

    PMID: 27803672
  7. 7

    Activating calcium-sensing receptor gene variants in China: a case report of hypocalcaemia and literature review.

    Guo S, Li X, Shan X

    Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(5)):500-504 doi:10.1515/jpem-2022-0623.

    PMID: 36935580
  8. 8

    The Effects of Diuretics on Mineral and Bone Metabolism.

    Alon US

    Pediatric endocrinology reviews : PER 2018; (15(4)):291-297 doi:10.17458/per.vol15.2018.a.DiureticsMineralBoneMetabolism.

    PMID: 29806749
  9. 9

    Thiazide diuretics for preventing calcium oxalate recurrent kidney stones: an updated systematic review, meta-analysis and trial sequential analysis of randomized controlled trials.

    Porto BC, Terada BD, Gonçalves FG, et al.

    Minerva urology and nephrology 2025; (77(3)):298-307 doi:10.23736/S2724-6051.25.05903-8.

    PMID: 40528770
  10. 10

    [Are thiazide diuretics ineffective with a glomerular filtration rate lower than 50 ml/min?]

    Hausberg M

    Innere Medizin (Heidelberg, Germany) 2024; (65(2)):180-184 doi:10.1007/s00108-023-01617-8.

    PMID: 38112725
  11. 11

    Chronic Hypoparathyroidism-Current and Emerging Therapies.

    Khan S, Khan AA

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(11)):1478-1487 doi:10.1016/j.eprac.2025.07.011.

    PMID: 40680836
  12. 12

    Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.

    Rejnmark L

    Endocrinology and metabolism (Seoul, Korea) 2024; (39(2)):262-266 doi:10.3803/EnM.2024.1916.

    PMID: 38572533
  13. 13

    New Directions in Treatment of Hypoparathyroidism.

    Tabacco G, Bilezikian JP

    Endocrinology and metabolism clinics of North America 2018; (47(4)):901-915 doi:10.1016/j.ecl.2018.07.013.

    PMID: 30390821
  14. 14

    Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model.

    Hannan FM, Gorvin CM, Babinsky VN, et al.

    JBMR plus 2020; (4(10)):e10402 doi:10.1002/jbm4.10402.

    PMID: 33103030
  15. 15

    Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).

    Roberts MS, Gafni RI, Brillante B, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019; (34(9)):1609-1618 doi:10.1002/jbmr.3747.

    PMID: 31063613
  16. 16

    In vivo treatment with calcilytic of CaSR knock-in mice ameliorates renal phenotype reversing downregulation of the vasopressin-AQP2 pathway.

    Ranieri M, Angelini I, D'Agostino M, et al.

    The Journal of physiology 2024; (602(13)):3207-3224 doi:10.1113/JP284233.

    PMID: 38367250

This page explains Autosomal Dominant Hypocalcemia (ADH) treatment strategies for educational purposes. It does not replace professional medical advice. Always consult your endocrinologist or nephrologist before adjusting your medications or calcium goals.

Get notified when new evidence is published on Autosomal dominant hypocalcemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.